Tags

Type your tag names separated by a space and hit enter

Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Behav Brain Res. 2007 Jan 25; 176(2):216-21.BB

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder, characterised by severe degeneration of basal ganglia, motor abnormalities, impaired cognitive function and emotional disturbances. Many of the distinct neuropathological features of HD are reproduced in rats by intrastriatal injections of the excitotoxin quinolinic acid (QA), and QA-induced excitotoxicity is partially prevented by administration of the A(2A) receptor antagonist prior to the QA injection. In this study, we assessed the neuroprotective effects of the adenosine A(2A) receptor antagonist SCH 58261 on the progressive behavioural alterations reported in the QA rat model of Huntington's disease. Male rats received i.p. SCH 58261 (0.01mg/kg) or vehicle 20min before a bilateral injection of quinolinic acid (QA, 300nmol/1mul) or its vehicle in the dorsal striatum. Motor activity and anxiety levels were analyzed in an open-field arena and in an elevated plus-maze at 2 weeks, 2 months and 6 months post-lesion. In QA-lesioned rats SCH 58261 prevented alterations of wall rearing behaviour starting from 2 weeks post-lesion while emotional changes (reduced anxiety) were back to control levels by 6 months post-lesion. These findings extend to the behavioural parameters the protective effects of SCH 58261 in the QA model of Huntington's disease.

Authors+Show Affiliations

Department of Cell Biology and Neuroscience, Istituto Superiore di Sanità, Viale Regina Elena 299, I-00161 Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17123640

Citation

Scattoni, Maria Luisa, et al. "Adenosine A2A Receptor Blockade Before Striatal Excitotoxic Lesions Prevents Long Term Behavioural Disturbances in the Quinolinic Rat Model of Huntington's Disease." Behavioural Brain Research, vol. 176, no. 2, 2007, pp. 216-21.
Scattoni ML, Valanzano A, Pezzola A, et al. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease. Behav Brain Res. 2007;176(2):216-21.
Scattoni, M. L., Valanzano, A., Pezzola, A., March, Z. D., Fusco, F. R., Popoli, P., & Calamandrei, G. (2007). Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease. Behavioural Brain Research, 176(2), 216-21.
Scattoni ML, et al. Adenosine A2A Receptor Blockade Before Striatal Excitotoxic Lesions Prevents Long Term Behavioural Disturbances in the Quinolinic Rat Model of Huntington's Disease. Behav Brain Res. 2007 Jan 25;176(2):216-21. PubMed PMID: 17123640.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease. AU - Scattoni,Maria Luisa, AU - Valanzano,Angelina, AU - Pezzola,Antonella, AU - March,Zena De, AU - Fusco,Francesca Romana, AU - Popoli,Patrizia, AU - Calamandrei,Gemma, Y1 - 2006/11/22/ PY - 2006/07/28/received PY - 2006/09/29/revised PY - 2006/10/05/accepted PY - 2006/11/25/pubmed PY - 2007/3/3/medline PY - 2006/11/25/entrez SP - 216 EP - 21 JF - Behavioural brain research JO - Behav Brain Res VL - 176 IS - 2 N2 - Huntington's disease (HD) is a progressive neurodegenerative disorder, characterised by severe degeneration of basal ganglia, motor abnormalities, impaired cognitive function and emotional disturbances. Many of the distinct neuropathological features of HD are reproduced in rats by intrastriatal injections of the excitotoxin quinolinic acid (QA), and QA-induced excitotoxicity is partially prevented by administration of the A(2A) receptor antagonist prior to the QA injection. In this study, we assessed the neuroprotective effects of the adenosine A(2A) receptor antagonist SCH 58261 on the progressive behavioural alterations reported in the QA rat model of Huntington's disease. Male rats received i.p. SCH 58261 (0.01mg/kg) or vehicle 20min before a bilateral injection of quinolinic acid (QA, 300nmol/1mul) or its vehicle in the dorsal striatum. Motor activity and anxiety levels were analyzed in an open-field arena and in an elevated plus-maze at 2 weeks, 2 months and 6 months post-lesion. In QA-lesioned rats SCH 58261 prevented alterations of wall rearing behaviour starting from 2 weeks post-lesion while emotional changes (reduced anxiety) were back to control levels by 6 months post-lesion. These findings extend to the behavioural parameters the protective effects of SCH 58261 in the QA model of Huntington's disease. SN - 0166-4328 UR - https://www.unboundmedicine.com/medline/citation/17123640/Adenosine_A2A_receptor_blockade_before_striatal_excitotoxic_lesions_prevents_long_term_behavioural_disturbances_in_the_quinolinic_rat_model_of_Huntington's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-4328(06)00534-1 DB - PRIME DP - Unbound Medicine ER -